Irlab Therapeutics AB (IRLAB.A)
XSTO XSTO Primary Summary
Irlab Therapeutics AB (IRLAB.A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Irlab Therapeutics AB ever had a stock split?
Irlab Therapeutics AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Gunnar Olsson CEO | XSTO Exchange | - ISIN |
| Sweden Country | 31 Employees | - Last Dividend | 28 May 2019 Last Split | - IPO Date |
Overview
IRLAB Therapeutics AB (publ), established in 2013 and based in Gothenburg, Sweden, focuses on the development of pharmaceuticals aimed at treating Parkinson's disease. Their innovative research and development pipeline caters to addressing various aspects of Parkinson's and other neurodegenerative disorders. The company is currently advancing both clinical and preclinical stage products through promising trials, aiming to tackle the complexities of Parkinson's disease symptoms and related conditions with novel therapeutic approaches.
Products and Services
- Mesdopetam
Currently in phase IIb/III clinical studies, Mesdopetam is developed to treat dyskinesia in Parkinson's disease patients. Dyskinesia is a common side effect of long-term dopamine therapy, characterized by involuntary, erratic movements. By targeting this condition, Mesdopetam could significantly improve the quality of life for those affected by Parkinson's disease.
- Pirepemat
In phase IIb clinical trial, Pirepemat addresses Postural dysfunction in Parkinson's disease, a challenging symptom that significantly impacts balance and mobility. This therapeutic approach underscores the company's commitment to tackling the broader motor symptoms of Parkinson’s that severely affect patients' independence and daily activities.
- Preclinical Stage Products
-
IRL942 - This research program is focused on developing treatments for neurodegenerative disorders and ageing, aiming at the core of these conditions to potentially slow their progression.
-
IRL1117 - Developed for the once-daily oral treatment of the hallmark symptoms of Parkinson's disease, IRL1117 represents the forefront of the company’s effort to create effective and manageable treatments for patients.
-
IRL757 - Specifically aiming to treat apathy in neurological diseases, IRL757 targets a symptom that substantially affects the quality of life but is often overlooked in treatment strategies for neurodegenerative diseases.
-
- P003
A research project dedicated to developing drugs for the treatment of newly diagnosed Parkinson’s disease. P003 signifies the company’s proactive approach in addressing Parkinson’s disease from its onset, potentially altering the disease's trajectory and impact on patients.
